in final draft guidance published Wednesday,

the National Institute for Health and Clinical Excellence recommended that Amgen's Prolia (denosumab) should be made available on the NHS to postmenopausal women at increased risk of osteoporotic fractures if other treatments are unsuitable.

Carole Longson, Health Technology Evaluation Centre Director at NICE, noted that the agency "felt that there was good quality evidence to show that denosumab is a useful addition to the treatment options available for women who can't have oral bisphosphonates.

" In June, the agency issued a similar preliminary recommendation, and final guidance is expected later in the year.

Prolia, which Amgen co-markets with GlaxoSmithKline in Europe, was approved in Europe in May.